Artal Group S.A. Fate Therapeutics Inc Transaction History

Artal Group S.A.

$1.58 Billion
Q2 2024

A detailed history of Artal Group S.A. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Artal Group S.A. holds 1,032,500 shares of FATE stock, worth $3.61 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares

1,032,500

Previous 360,311 186.56%

Holding current value

$3.61 Million

Previous $2.64 Million 28.06%

% of portfolio

0.21%

Previous 0.14%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $2.19 Million - $4.76 Million	672,189 Added 186.56%	1,032,500 $3.39 Million
Q1 2024 May 13, 2024	BUY	$3.54 - $8.35 $1.28 Million - $3.01 Million	360,311 New	360,311 $2.64 Million
Q2 2022 Aug 11, 2022	BUY	$17.78 - $42.39 $10.7 Million - $25.4 Million	600,000 Added 30.0%	2,600,000 $64.4 Million
Q1 2022 May 12, 2022	BUY	$29.67 - $60.28 $5.93 Million - $12.1 Million	200,000 Added 11.11%	2,000,000 $77.5 Million
Q4 2021 Feb 11, 2022	BUY	$47.84 - $64.34 $16.7 Million - $22.5 Million	350,000 Added 24.14%	1,800,000 $105 Million
Q3 2021 Nov 12, 2021	BUY	$59.27 - $95.73 $5.93 Million - $9.57 Million	100,000 Added 7.41%	1,450,000 $85.9 Million
Q2 2021 Aug 13, 2021	BUY	$67.25 - $92.52 $3.36 Million - $4.63 Million	50,000 Added 3.85%	1,350,000 $117 Million
Q1 2021 May 14, 2021	SELL	$72.16 - $117.4 $7.22 Million - $11.7 Million	-100,000 Reduced 7.14%	1,300,000 $107 Million
Q4 2020 Feb 11, 2021	SELL	$38.09 - $100.95 $3.81 Million - $10.1 Million	-100,000 Reduced 6.67%	1,400,000 $127 Million
Q3 2020 Nov 13, 2020	SELL	$30.41 - $40.5 $9.12 Million - $12.2 Million	-300,000 Reduced 16.67%	1,500,000 $60 Million
Q2 2020 Aug 14, 2020	SELL	$20.21 - $35.23 $6.06 Million - $10.6 Million	-300,000 Reduced 14.29%	1,800,000 $61.8 Million
Q1 2020 May 14, 2020	BUY	$17.28 - $31.88 $1.73 Million - $3.19 Million	100,000 Added 5.0%	2,100,000 $46.6 Million
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $7.74 Million - $11.3 Million	500,000 Added 33.33%	2,000,000 $31.1 Million
Q2 2019 Aug 09, 2019	SELL	$15.61 - $20.44 $4.68 Million - $6.13 Million	-300,000 Reduced 16.67%	1,500,000 $30.5 Million
Q1 2019 May 10, 2019	SELL	$13.15 - $18.71 $4.6 Million - $6.55 Million	-350,000 Reduced 16.28%	1,800,000 $31.6 Million
Q4 2018 Feb 11, 2019	SELL	$11.48 - $16.98 $459,200 - $679,200	-40,000 Reduced 1.83%	2,150,000 $27.6 Million
Q3 2018 Nov 09, 2018	BUY	$8.75 - $16.29 $4.29 Million - $7.98 Million	490,000 Added 28.82%	2,190,000 $35.7 Million
Q2 2018 Aug 10, 2018	BUY	$9.16 - $13.48 $7.79 Million - $11.5 Million	850,000 Added 100.0%	1,700,000 $19.3 Million
Q1 2018 May 10, 2018	BUY	$6.3 - $13.77 $5.36 Million - $11.7 Million	850,000 New	850,000 $8.3 Million

Others Institutions Holding FATE

# of Institutions

190

Shares Held

123M

Call Options Held

15K

Put Options Held

14K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $340M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Account